CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro
Article 2004 en
Authors
KV
Kurt Vermeire
KP
Katrien Princen
SH
Sigrid Hatse
Abstract
1 min read
Compounds that can specifically downmodulate the CD4 receptor in PBMC have broad-spectrum anti-HIV activity against primary isolates and act synergistically when used in conjunction with currently available antiretroviral drugs. They deserve further study as potential candidate anti-HIV drugs.
Discussion(0)
No comments yet. Be the first to comment.